Share Capital (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended													12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jan. 31, 2022	Oct. 31, 2021	Sep. 30, 2021	Mar. 31, 2021	Jan. 31, 2021	Jun. 30, 2020	Feb. 29, 2020	Jan. 31, 2020	Nov. 30, 2019	Sep. 30, 2019	Mar. 31, 2018	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Capital [Line Items]
Warrants outstanding to purchase common stock														3,103,864	2,775,996
Options granted														2,315,645	1,775,450	1,482,250
Options Outstanding Weighted Average Remaining Contractual Life in Years														7 years 4 months 24 days
Options Exercisable Weighted Average Remaining Contractual Life in Years														5 years 10 months 24 days
Aggregate fair value of options vested														$ 13,752	$ 8,271	$ 3,698
Unrecognized stock-based compensation cost														$ 49,105
Unrecognized stock-based compensation expected to be recognized over a period														2 years 9 months 10 days
Warrants exercise description														The Company may not affect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company’s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company’s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to the Company.
Amended and Restated Stock Option Plan [Member]
Share Capital [Line Items]
Vesting period														4 years
Maximum term of each option exercised														10 years
Options granted														0
2019 Inducement Plan [Member]
Share Capital [Line Items]
Options granted												0
Common shares reserved for issuance												400,000
Amended and Restated 2014 Plan [Member]
Share Capital [Line Items]
Vesting period								4 years
Maximum term of each option exercised								10 years
Common shares reserved for issuance								9,300,000						5,646,490
Number of restricted share awards, restricted share unit awards or performance awards available for issue								1,000,000
Common Shares [Member]
Share Capital [Line Items]
Shares issued														9,357,348	16,143,472	6,759,187
Conversion of shares		1,016,000												1,016,000				1,852,000
Jefferies and Stifel [Member] | ATM [Member]
Share Capital [Line Items]
Sale proceeds of common shares							$ 10,693			$ 37,796							$ 10,729
Jefferies and Stifel [Member] | ATM [Member] | Maximum [Member]
Share Capital [Line Items]
Gross proceeds from issuable of common stock											$ 50,000			$ 250,000
Jefferies and Stifel [Member] | ATM [Member] | Common Shares [Member]
Share Capital [Line Items]
Shares issued							733,000			2,446,687				0			805,643
Jefferies and Stifel [Member] | Underwritten Public Offering [Member]
Share Capital [Line Items]
Sale proceeds of common shares						$ 107,922
Shares issued						5,135,135
Shares price						$ 18.50
Warrants outstanding to purchase common stock						1,081,081
Warrants issued price per pre funded warrant						$ 18.4999
Warrants exercise price per common share						$ 0.0001
Sale proceeds from issuance of pre funded warrants														$ 75,103
Number of warrants exercised														0
Jefferies and Stifel [Member] | Over Allotment [Member]
Share Capital [Line Items]
Shares issued						810,810				562,500
Jefferies, Stifel and Guggenheim Securities, LLC [Member] | Underwritten Public Offering [Member]
Share Capital [Line Items]
Sale proceeds of common shares									$ 64,660
Jefferies, Stifel and Guggenheim Securities, LLC [Member] | Underwritten Public Offering [Member] | Common Shares [Member]
Share Capital [Line Items]
Shares issued										3,750,000
Shares price										$ 16.00
Jefferies LLC SVB Leerink LLC and Stifel Nicolaus Company Incorporated [Member] | Underwritten Public Offering [Member]
Share Capital [Line Items]
Sale proceeds of common shares				$ 323,938
Shares issued				10,000,000
Shares price				$ 29.50
Warrants outstanding to purchase common stock				1,694,915
Warrants issued price per pre funded warrant				$ 29.4999
Warrants exercise price per common share				$ 0.0001
Jefferies LLC SVB Leerink LLC and Stifel Nicolaus Company Incorporated [Member] | Over Allotment [Member]
Share Capital [Line Items]
Shares issued				1,525,423
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member]
Share Capital [Line Items]
Sale proceeds of common shares			$ 8,250		$ 5,500
Shares issued			258,986		275,337
Aggregate purchase price per share			$ 31.855		$ 19.9755
Premium			$ 374		$ 770
Jefferies, Stifel, J.P. Morgan Securities LLC and SVB Securities LLC [Member] | Underwritten Public Offering [Member]
Share Capital [Line Items]
Sale proceeds of common shares	$ 269,890
Shares issued	9,098,362
Shares price	$ 30.50
Warrants outstanding to purchase common stock	327,868
Warrants issued price per pre funded warrant	$ 30.4999
Warrants exercise price per common share	$ 0.0001
Jefferies, Stifel, J.P. Morgan Securities LLC and SVB Securities LLC [Member] | Over Allotment [Member]
Share Capital [Line Items]
Shares issued	1,229,508
Series1 Preferred Shares
Share Capital [Line Items]
Conversion of shares		1,016,000																1,852,000
BVF Partners L.P [Member] | Exchange Agreement [Member] | Common Shares [Member]
Share Capital [Line Items]
Shares cancelled													2,868,000
BVF Partners L.P [Member] | Exchange Agreement [Member] | Series1 Preferred Shares
Share Capital [Line Items]
Preferred shares convertible into common shares													one-for-one
Shares issued													2,868,000